The downgrade from Overweight to Equal-Weight suggests that Barclays sees less upside potential in Reata Pharmaceuticals, which could negatively impact the stock. However, the raised price target from $110 to $172 indicates that Barclays still sees significant value in the stock, which could offset the negative impact of the downgrade. Therefore, the short-term impact on the stock is likely to be neutral.